A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety and tolerability of MRG002 in combination
with HX008 in patients with HER2-expressed advanced malignant solid tumors; and to , explore
the maximum tolerated dose (MTD), and to determine the recommended phase II dose (RP2D) of
combination therapy; , and to evaluate the preliminary efficacy, pharmacokinetics, and
immunogenicity of combination therapy in the targeted study population.